RANIRani Therapeutics Holdings Inc - Ordinary Shares Class A

Rani Therapeutics (NASDAQ:RANI) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-rani-therapeutics-holdings-inc-stock...

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company...

Lake Street Capital initiated coverage on Rani Therapeutics in a research report on Tuesday. They set a "buy" rating and a $9.00 price target on the stock...

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company...

Canaccord Genuity Group lowered their target price on Rani Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Rani Therapeutics in a report issued on Friday, March...

HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Rani Therapeutics in a research report on Friday...

Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a transformational 2025 during the company's fourth-quarter and full-year earnings call, pointing to progress advancing...

Rani Therapeutics (NASDAQ:RANI - Get Free Report) posted its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The...